KYMERA THERAPEUTICS, INC. Cost of Revenue
KYMERA THERAPEUTICS, INC. (KYMR) reported Cost of Revenue of $65.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. cost of revenue for the quarter ending 2026-06-30 was $65.00M, a 466.40% increase year-over-year.
- KYMERA THERAPEUTICS, INC. cost of revenue for the quarter ending 2026-03-31 was $34.37M, a 55.50% increase year-over-year.
- KYMERA THERAPEUTICS, INC. cost of revenue for the quarter ending 2025-12-31 was $2.87M, a 61.18% decline year-over-year.
- KYMERA THERAPEUTICS, INC. cost of revenue for the quarter ending 2025-09-30 was $2.76M, a 26.12% decline year-over-year.
- KYMERA THERAPEUTICS, INC. cost of revenue for fiscal 2025 was $39.21M, a 16.70% decline from fiscal 2024.
- KYMERA THERAPEUTICS, INC. cost of revenue for fiscal 2024 was $47.07M, a 40.11% decline from fiscal 2023.
- KYMERA THERAPEUTICS, INC. cost of revenue for fiscal 2023 was $78.59M, a 67.84% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. cost of revenue for fiscal 2022 was $46.83M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $65.00M 10-Q · filed 2026-08-05 | $99.36M 10-Q · filed 2026-08-05 | $102.23M derived: sum of 3 quarters · filed 2026-08-05 | $105.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $34.37M 10-Q · filed 2026-04-30 | $37.23M derived: sum of 2 quarters · filed 2026-04-30 | $40.00M derived: sum of 3 quarters · filed 2026-04-30 | $51.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.63M derived: sum of 2 quarters · filed 2026-02-26 | $17.11M derived: sum of 3 quarters · filed 2026-08-05 | $39.21M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.76M 10-Q · filed 2025-11-04 | $14.24M derived: sum of 2 quarters · filed 2026-08-05 | $36.34M 10-Q · filed 2025-11-04 | $43.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $11.48M 10-Q · filed 2026-08-05 | $33.58M 10-Q · filed 2026-08-05 | $40.97M derived: sum of 3 quarters · filed 2026-08-05 | $44.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $22.10M 10-Q · filed 2026-04-30 | $29.49M derived: sum of 2 quarters · filed 2026-04-30 | $33.23M derived: sum of 3 quarters · filed 2026-04-30 | $58.88M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.13M derived: sum of 2 quarters · filed 2026-02-26 | $36.78M derived: sum of 3 quarters · filed 2026-02-26 | $47.07M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.74M 10-Q · filed 2025-11-04 | $29.39M derived: sum of 2 quarters · filed 2025-11-04 | $39.68M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $25.65M 10-Q · filed 2025-08-11 | $35.94M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $10.29M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $78.59M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $46.83M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |